Novo Holdings

Benchmark Genetics is a prominent company in aquaculture genetics, specializing in the development of genetic material for various species, particularly salmon, shrimp, and tilapia. With extensive experience from 30 applied breeding programs across 16 countries, the company is recognized as a leading provider of genetics services in the industry. Their approach is innovation-driven, utilizing advanced breeding technologies such as Quantitative Trait Loci (QTL) and Genomic Selection. Benchmark Genetics places significant emphasis on customer collaboration, fostering long-term partnerships with leading aquaculture businesses to enhance genetic improvements and develop new products. In addition to their genetic offerings, the company provides comprehensive technical support to ensure clients maximize the potential of their genetic resources. Their dedicated sales teams include technical specialists knowledgeable about their focus species and various production systems, including Recirculating Aquaculture Systems (RAS).

Stingray Marine Solutions AS is a Norwegian technology firm based in Oslo, specializing in innovative solutions for the aquaculture industry, specifically in the removal of sea lice from fish. Founded in 2010, the company has developed an advanced optical delousing system that employs camera vision and laser technology to detect and eliminate sea lice from salmon in net pens. This automated process enhances fish health management by minimizing the need for physical handling of the fish, thereby increasing productivity in salmon farming. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS and has its origins in the entrepreneurial vision of Esben Beck, who has been involved in technology development since 1999.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in the manufacturing of heavy-duty single-use plastic containers and packaging products designed for the transportation of liquids, particularly in the pharmaceuticals and biopharma sectors. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, to enhance fluid logistics processes and minimize the risk of leakage or bio-contamination. By providing tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid transport, addressing the specific needs of its clients in the pharmaceutical industry.

Catalent Pharma Solutions provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industries worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. Development and Clinical Services offers manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials, along with analytical chemical and cell-based testing, respiratory product formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology and product development. The Oral Technologies segment focuses on formulation, development, and manufacturing for oral dose forms, including conventional tablets and capsules, controlled-release formulations, and proprietary oral delivery technologies. The Sterile Technologies segment provides formulation and development for injectable drugs and fills products into vials, pre-filled syringes, bags, and other sterile formats, with blow-fill-seal technology for integrated dose form creation. Packaging Services delivers packaging for pharmaceuticals, biologics, consumer health, and veterinary products, including blisters, bottles, pouches, unit doses, and printed components.

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

The Ritedose Corporation specializes in contract manufacturing of small-volume pharmaceutical liquids using blow-fill-seal technology. It focuses on sterile and non-sterile inhalation vials, eye drops, ear drops, oral liquids, and delivery systems for the respiratory market.

Established over two decades ago, BBI Group is a trusted partner to prominent diagnostic and healthcare organizations. Initially founded on the success of its high-quality gold reagents, the company has since expanded into three business units, specializing in diagnostic assay development and manufacturing across various sectors, as well as supplying consumer healthcare products.

Altasciences is a mid-sized contract research organization based in Laval, Quebec, specializing in preclinical and clinical pharmacology services for pharmaceutical and biotechnology companies. The company provides a comprehensive range of services, including preclinical safety testing, clinical pharmacology, drug formulation, manufacturing, bioanalysis, medical writing, biostatistics, and clinical monitoring. By offering integrated and customizable solutions, Altasciences supports sponsors in making informed decisions throughout early drug development. The company's focus is on accelerating the clinical research process to help bring effective drugs to market more rapidly, ultimately improving access for patients in need.

Oxford Biomedica is a biopharmaceutical company focused on gene and cell therapy, specializing in the development, manufacturing, and advancement of lentiviral vector-based medicines and related cell therapies. The company leverages its LentiVector platform to deliver therapeutic genes into non-dividing cells and collaborates with major pharmaceutical firms to progress both internal candidates and externally funded programs. Its internal pipeline targets diseases of the eye and the central nervous system, while ongoing partnerships span multiple therapeutic areas across Phase I/II and beyond. Oxford Biomedica also operates as a contract development and manufacturing organization, offering viral vector development and manufacturing services through OXB Solutions. Founded in 1995 and headquartered in Oxford, United Kingdom, the company maintains a global collaboration network with industry and academic partners.

Sonion designs and manufactures advanced miniature components and solutions for various markets. Their product range includes balanced armature drivers, microphones, biometric sensors, wireless coils, bone conduction sensors, RIC assemblies, and user interfaces.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on anti-infective products, developing and manufacturing fermented and semi-synthetic active pharmaceutical ingredients and finished dosage forms for global pharmaceutical clients. It offers contract manufacturing services for antibiotics, from custom synthesis of clinical trial material to large-scale production of marketed products, along with stability testing, filling and packaging of dry powder filled vials and lyophilized vials. The company is a leading supplier of vancomycin and colistimethate sodium and operates manufacturing facilities in Europe and Asia with a global customer base across more than 70 countries. Xellia adheres to current Good Manufacturing Practice and maintains regulatory approvals from relevant authorities.